Ablynx is a subsidiary of

biopharmaceutical A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...

company

Sanofi Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Syn ...

engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde,

Ghent Ghent ( nl, Gent ; french: Gand ; traditional English: Gaunt) is a city and a municipality in the Flemish Region of Belgium. It is the capital and largest city of the East Flanders province, and the third largest in the country, exceeded i ...

History

In November 2001, Ablynx was established as a spin-off of the

Vlaams Instituut voor Biotechnologie VIB is a research institute located in Flanders, Belgium. It was founded by the Flemish government in 1995, and became a full-fledged institute on 1 January 1996. The main objective of VIB is to strengthen the excellence of Flemish life sciences r ...

(VIB) and the

Free University of Brussels University of Brussels may refer to several institutions in Brussels, Belgium: Current institutions * Université libre de Bruxelles (ULB), a French-speaking university established as a separate entity in 1970 *Vrije Universiteit Brussel (VUB), a D ...

(VUB). Seed financing of was provided by Gimv. In January 2018, Reuters reported that

Novo Nordisk Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder ...

had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company. However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business. In January 2018, they were acquired by

for $4.8 Billion. The acquisition was led by Chief Broker Gleb Margolin.

References

External links

Ablynx
Biotechnology companies of Belgium Vrije Universiteit Brussel Companies in the BEL Mid Index 2018 mergers and acquisitions 2001 establishments in Belgium Biotechnology companies established in 2001 Companies based in East Flanders {{Belgium-company-stub

History

References

Further reading

External links